This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: Evidence of a relation between use of lipid lowering drugs and cognitive outcomes is mixed. This study aimed to test the association between use of statins and incidence of dementia and cognitive impairment without dementia (CIND) over 5 years of follow-up.
Methods: Data were from a population-based cohort study comprising 1,789 older Mexican Americans. All participants had cognitive and clinical evaluations performed every 12 to 15 months. Participants who fell below specified cutpoints on cognitive tests were then evaluated clinically. Dementia diagnoses were finalized by an adjudication team. A total of 1,674 participants free of dementia/CIND at baseline were included in these analyses. Statin use was verified at each participant's home by medicine cabinet inspection. Cox proportional hazards models were used to evaluate the association between statin use and incidence of dementia/CIND.
Results: Overall, 452 of 1,674 participants (27%) took statins at any time during the study. Over the 5-year follow-up period, 130 participants developed dementia/CIND. In Cox proportional hazards models adjusted for education, smoking status, presence of at least one APOE ε4 allele, and history of stroke or diabetes at baseline, persons who had used statins were about half as likely as those who did not use statins to develop dementia/CIND (HR = 0.52; 95% CI 0.34, 0.80).
Conclusion: Statin users were less likely to have incident dementia/cognitive impairment without dementia during a 5-year follow-up. These results add to the emerging evidence suggesting a protective effect of statin use on cognitive outcomes.
Glossary
- 3MSE=
- Modified Mini-Mental State Examination;
- AD=
- Alzheimer disease;
- ATP=
- Adult Treatment Panel;
- CDC=
- Centers for Disease Control;
- CIND=
- cognitive impairment without dementia;
- DSM-IV=
- Diagnostic and Statistical Manual of Mental Disorders–IV;
- FPG=
- fasting plasma glucose;
- IQCODE=
- Informant Questionnaire on Cognitive Decline in the Elderly;
- LDL-C=
- low density-lipoprotein cholesterol;
- LLT=
- lipid lowering therapy;
- MCI=
- mild cognitive impairment;
- NINCDS-ADRDA=
- National Institute of Neurologic and Communicative Disorders and Stroke–Alzheimer Disease and Related Disorders Association;
- PROSPER=
- Prospective Study of Pravastatin in the Elderly;
- SALSA=
- Sacramento Area Latino Study on Aging;
- SENAS=
- Spanish English Neuropsychological Assessment Scales;
- SEVLT=
- Spanish and English Verbal Learning Test.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
- Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study
- Reply from the authors
- Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study
- Reply from the authors
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Emulating a target trial of statin use and risk of dementia using cohort data
Association of statin use with cognitive decline in elderly African Americans
Outcomes after thrombolysis in AIS according to prior statin use
Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease